CIS Pharma demonstrates successful in-vivo biodistribution study for Oncology drug carrier

Bubendorf, December 8, 2020 - CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested in a [...]

CIS Pharma demonstrates in-vitro proof of concept for its ’s Oncology drug delivery technology

Bubendorf, October 15, 2020 - CIS Pharma’s drug carrier technology has reached invitro proof of concept. A model antibody (Trastuzumab) was conjugated to two polymer carriers that were loaded with [...]

CIS Pharma identifies lead polymer carrier for Oncology

Bubendorf, May 14, 2020 - CIS Pharma’s polymer expert team has successfully reached the next milestone in its synthesis of the lead polymer carrier. Both analytical protocols as well as [...]

CIS Pharma Corona update

Bubendorf, April 2, 2020 - CIS Pharma’s pipeline developments will experience some delay as a result of the Corona lock downs. Our Campus remains fully operational due to adequate space [...]

CIS Pharma’s polymer-drug carriers successfully loaded with Lu-177 and In-111

Bubendorf, Switzerland, Wednesday, January 8, 2020 - In several laoding experiments Lutetium-177 and Indium-111 were loaded to CIS Pharma’s polymer-drug carriers, at high efficiency reates. Labeling density was close the [...]

CIS Pharma PEEK implant program has reached the first milestone

Bubendorf, Switzerland, Thursday, December 12, 2019 - A new method for the modification of PEEK surfaces was established that significantly increases hydrophilicity of the material surface. The novel method is [...]

CIS Pharma’s polymer-drug carriers to load radioisotopes show excellent performance in a multiparameter toxicity study

Bubendorf, Switzerland, Monday, December 9, 2019 - CIS Pharm has tested several of its new polymer-drug carriers to conjugate radionuclides in a multiparameter cytotoxicity study at Cyprotex, a CRO based [...]

CIS Pharma Christmas event in Arlesheim on ice

Arlesheim, Switzerland, Friday, December 6, 2019 - The team of CIS Pharma sets out on sheer ice, armed with stone and broom. After a short introduction, we are ready to play [...]

CIS Pharma successfully conjugated a model antibody to its polymer-drug carrier comprising radioisotopes

Bubendorf, Switzerland, Friday, November 1, 2019 - Within the scope of the proof-of-concept study at the Paul Scherer Institute, a number of polymer-drug carriers enabling the conjugation of different amounts [...]

CIS Pharma and the University of Appplied Sciences present their bio-membrane project at the Nano-Tech Event in Baden

Baden, Switzerland, Tuesday, October 29, 2019 - CIS Pharma and the University of Applied Sciences, FHNW Muttenz, are giving a talk at the Nano-Tech Apèro of the Swiss Nanoscience Institute, [...]